|
||||||||||||||||||||||||||||||||
|
About Enlyton Intellectual Property Enlyton has a diverse intellectual property portfolio, with multiple issued U.S. patents and foreign counterparts, and pending U.S. and foreign patent applications. A portion of these patents addresses a family of monoclonal antibodies for which Enlyton has secured a worldwide exclusive license from the National Institutes of Health. Collectively, this intellectual property addresses novel molecular targets for use in cancer imaging; the real-time detection and surgical removal of occult cancerous tissue; tumor margin assessment; fluorescence-based cancer detection, cancer diagnostics and prognostication, and targeted drug delivery. | |||||||||||||||||||||||||||||||
| Enlyton, Ltd. Corporation | All Rights Reserved | 7700 Rivers Edge Drive, Columbus, OH 43235 | 614-888-9220 | ||||||||||||||||||||||||||||||||